Swiss Helsinn Group and Mundipharma China Pharmaceutical will now sell ALOXI IV in China, as it got approval from the National Medical Products Administration (NMPA), which is the first Helsinn cancer supportive care in China, which will be mareketed by Mundipharma China Pharmaceutical.
Riccardo Braglia, Helsinn Group Vice Chairman and CEO, looks forward to be selling the company’s first cancer supportive care product in China. He noted that in the countries where ALOXI IV has been launched so far, it has been central to the prevention of CINV for many years and has helped define the standard of care for this condition. “In China, we are collaborating with our longstanding and trusted partner, Mundipharma China Pharmaceutical, and we look forward to working with them to bring this product to the many patients in China that suffer from CINV,” Braglia was quoted as saying in Helsinn’s press release on Monday.
Peter Wang, Mundipharma Pharmaceutical Greater China CEO, said: “ I’m more than happy to witness such a milestone of Mundipharma China Pharmaceutical to align a strategic partnership with Helsinn, and therefore to introduce ALOXI IV focusing on CINV treatment with cutting-edge technology and high quality to China market. This milestone not only enriches Mundipharma China’s portfolio, but definitely is to benefit millions of China’s patients, which is in line with the company’s insight and vision, ‘Bring more to life.”
ALOXI injection 0.25 mg/5 ml was approved on November 8th, 2018 in China and is indicated in adults for the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy, and prevention of acute and delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy. It is also indicated in pediatric patients aged 1 month to less than 17 years for the prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy.